Showing 1461-1470 of 5603 results for "".
Understanding the Mechanism Behind a Treatment Approach in Indolent Systemic Mastocytosis (ISM)
https://reachmd.com/programs/medical-industry-feature/mechanism-treatment-approach-indolent-systemic-mastocytosis-ism/32766/Historically, indolent systemic mastocytosis (ISM) care focused on treating symptoms. AYVAKIT® (avapritinib) targets the KIT D816V mutation, the underlying cause of ISM.3,4 Learn how AYVAKIT can play a role in treating patients with ISM.1A Tale of Two Cities: Social Distancing in the 1918 Influenza Pandemic
https://reachmd.com/programs/covid-19-frontlines/a-tale-of-two-cities-social-distancing-in-the-1918-influenza-pandemic/11357/Countries all over the world have enforced social distancing amid the COVID-19 pandemic, but for the US, this isn’t an entirely new concept.Advances in the Management of Moderate-to-Severe Atopic Dermatitis
https://reachmd.com/programs/cme/advances-in-the-management-of-moderate-to-severe-atopic-dermatitis/10967/This multidisciplinary faculty panel and a patient deliberate over challenging topics in moderate-to-severe atopic dermatitis.Clinical Reflections®: Reflecting on Missed Opportunities in Nontuberculous Mycobacteria Lung Disease
https://reachmd.com/programs/cme/clinical-reflections-reflecting-missed-opportunities-nontuberculous-mycobacteria-lung-disease/11059/Explore the recognition and management of nontuberculous mycobacteria lung disease through two engaging patient cases.Help Protect Your Older Patients This Flu Season: Examining Real-World Data
https://reachmd.com/programs/medical-industry-feature/help-protect-your-older-patients-this-flu-season-examining-real-world-data/26660/Dive into data comparing adjuvanted trivalent influenza and high dose trivalent influenza vaccines in preventing test-confirmed flu hospitalizations among older adults.Shared Financial Incentives for Both Physicians and Patients Improved Cholesterol Levels
https://reachmd.com/programs/the-jama-report/shared-financial-incentives-both-physicians-and-patients-improved-cholesterol-levels/7744/[Read the Article] Financial incentives for physicians or patients are one way healthcare organizations are trying to improve health outcomes. A new study examined whether providing these financial incentives would help improve low-density lipoprotein cholesterol (LDL-C) in patients with a high-riskStudy Compares Health Care Usage, Cost in Developed Countries for Patients Dying with Cancer
https://reachmd.com/programs/the-jama-report/study-compares-health-care-usage-cost-developed-countries-patients-dying-cancer/7897/[Read the Article] To some, end of life care in the United States is considered resource intensive, expensive, and inattentive to patients' needs. So how does the United States compare to other countries? A new study examined several health care measures at the end of life for cancer patients in fivStudy Examines Death Rates, Hospitalizations, and Cost Reductions for Medicare Patients
https://reachmd.com/programs/the-jama-report/study-examines-death-rates-hospitalizations-and-cost-reductions-medicare-patients/7638/[Read the Article] America's landmark health care programs, Medicare and Medicaid, celebrate their 50th anniversaries on July 30th. Over the past five decades, the United States healthcare system has experienced dynamic changes, most notably in recent years with improvements in technology, care deliRadiologic Differential Diagnosis of Multiple Sclerosis
https://reachmd.com/diseases-diagnoses/ms-immune-disorders/radiologic-differential-diagnosis-of-multiple-sclerosis/54601/This article provides an overview of the radiographic features that are shared and those that are distinct among multiple sclerosis, aquaporin-4 antibody–positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte protein antibody–associated disease.HER2 in Bladder Cancer: Breaking Through the Molecular Frontier
https://reachmd.com/programs/cme/her2-in-bladder-cancer-breaking-through-the-molecular-frontier/35561/Explore HER2 as a therapeutic target in bladder cancer, from molecular testing to HER2-directed treatment strategies and multidisciplinary AE management.